Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thioguanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HBB | P68871 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioguanine SCHEMBL11551819 | 0.91 | PNP (0.45) | PNPALDH1A1HBBSMN1; SMN2MAPT | |
| Thioguanine SCHEMBL11551825 | 0.89 | PNP (0.43) | PNPALDH1A1HBBSMN1; SMN2MAPT | |
| Thioguanine SCHEMBL1176577 | 0.81 | PNP (0.62) | PNPALDH1A1HBBSMN1; SMN2MAPT | |
| Thioguanine SCHEMBL3701 | 0.81 | PNP (0.62) | PNPALDH1A1HBBSMN1; SMN2MAPT | |
| Guanine SCHEMBL28067184 | 0.80 | PNP (0.79) | PNPALDH1A1HBBSMN1; SMN2MAPT | |
| Thioguanine SCHEMBL27833745 | 0.79 | PNP (0.61) | PNPALDH1A1HBBSMN1; SMN2MAPT | |
| Thioguanine SCHEMBL28189108 | 0.79 | PNP (0.61) | PNPALDH1A1HBBSMN1; SMN2MAPT | |
| Thioguanine SCHEMBL27871419 | 0.79 | PNP (0.61) | PNPALDH1A1HBBSMN1; SMN2MAPT | |
| Thioguanine SCHEMBL28385604 | 0.79 | PNP (0.61) | PNPALDH1A1HBBSMN1; SMN2MAPT | |
| Hypoxanthine SCHEMBL8161237 | 0.78 | ALDH1A1 (0.63) | PNPALDH1A1HBBSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624877-B2 | Composition and method for treatment of symptoms associated with various skin conditions | THERACEUTIX, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180133196-A1 | COMPOSITION AND METHOD FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH VARIOUS SKIN CONDITIONS | THERACEUTIX, LLC | 2018-05-17 | — | — | US | disclosed |
| US-9968590-B2 | Composition and method for treatment of symptoms associated with various skin conditions | THERACEUTIX, LLC (US) | 2018-05-15 | — | — | US | disclosed |
| US-20140212362-A1 | COMPOSITION AND METHOD FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH VARIOUS SKIN CONDITIONS | THERACEUTIX, LLC (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2013049272-A2 | COMPOSITION AND METHOD FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH VARIOUS SKIN CONDITIONS | THERACEUTIX, LLC (US) | 2013-04-04 | — | — | WO | disclosed |
| US-6649591-B2 | Dithiocarbamates linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein); treating cerebral stroke and other ischemia/reperfusion injury | MEDINOX, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030181495-A1 | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor | MEDINOX, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6596770-B2 | Disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of)the species that induce the expression of nitric oxide synthase | MEDINOX, INC. | 2003-07-22 | — | — | US | disclosed |
| EP-1089723-A4 | THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR | MEDINOX INC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6589991-B1 | Treating diseases associated with nuclear factor kappa B pathway; nitric oxide synthase inhibitors, antiinflammatory agents | MEDINOX, INC. | 2003-07-08 | — | — | US | disclosed |
| EP-1089723-A1 | THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR | Medinox, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-0938309-A4 | METHODS FOR IN VIVO REDUCTION OF IRON LEVELS AND COMPOSITIONS USEFUL THEREFOR | MEDINOX INC (US) | 2000-12-20 | — | — | EP | disclosed |
| US-6093743-A | FOR IN VIVO REDUCTION OF LEVELS OF NITRIC OXIDE, SUCH AS ARE INDUCED BY A VARIETY OF DISEASE STATES, AND FOR TREATMENT OF INFECTIOUS AND/OR INFLAMMATORY CONDITIONS | MEDINOX INC. (US) | 2000-07-25 | — | — | US | disclosed |
| WO-1999066918-A9 | THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR | MEDINOX INC (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-1999066918-A1 | THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR | MEDINOX, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0938309-A1 | METHODS FOR IN VIVO REDUCTION OF IRON LEVELS AND COMPOSITIONS USEFUL THEREFOR | Medinox, Inc. (US) | 1999-09-01 | — | — | EP | disclosed |
| EP-0927159-A1 | POLYDITHIOCARBAMATE-CONTAINING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | Medinox, Inc. (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998011066-A1 | POLYDITHIOCARBAMATE-CONTAINING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | MEDINOX, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998009626-A1 | METHODS FOR IN VIVO REDUCTION OF IRON LEVELS AND COMPOSITIONS USEFUL THEREFOR | MEDINOX, INC. (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1997032585-A1 | COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS AND COMPOSITIONS USEFUL THEREFOR | MEDINOX, INC. (US) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140212362-A1 | COMPOSITION AND METHOD FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH VARIOUS SKIN CONDITIONS | OAT, CUTA, KRT18 | PNP 887/4885ALDH1A1 2297/4885HBB 3674/4885 |
| US-10624877-B2 | Composition and method for treatment of symptoms associated with various skin conditions | OAT, CUTA, KRT18 | PNP 887/4885ALDH1A1 2297/4885HBB 3674/4885 |
| US-20180133196-A1 | COMPOSITION AND METHOD FOR TREATMENT OF SYMPTOMS ASSOCIATED WITH VARIOUS SKIN CONDITIONS | OAT, CUTA, KRT18 | PNP 887/4885ALDH1A1 2297/4885HBB 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.